Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA VI: NORD Wants Reviewers To Be More Accessible

Executive Summary

As rare disease experts become part of orphan drug reviews, stakeholder group says they also should be more accessible to the public.

You may also be interested in...



US FDA Planning Another Patient Group To Boost Involvement

Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.

US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'

FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.

Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?

Agency is still working to get oncology center of excellence off the ground and has other large pending reorganizations that could take precedence.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS118982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel